Yes, Medicaid covers insulin in all 50 states. While outpatient prescription drug coverage is technically an optional Medicaid benefit, every state has chosen to include it in their program. Insulin falls under this pharmacy benefit, so if you’re enrolled in Medicaid, you have coverage for insulin products. The specifics of which insulin brands are preferred, what your copay looks like, and how quickly you can get it depend on your state and the type of Medicaid plan you’re in.
How Medicaid Formularies Affect Your Insulin Options
Medicaid doesn’t just hand you any insulin you want. Each state maintains a preferred drug list, sometimes called a formulary, that determines which insulin products are covered with the fewest hurdles. If your doctor prescribes an insulin that’s on your state’s preferred list, you can typically fill it at the pharmacy without extra steps. If the prescribed insulin isn’t preferred, you may need prior authorization, meaning your doctor has to submit paperwork explaining why that specific product is medically necessary before the pharmacy can dispense it.
States build these lists based partly on the rebates drug manufacturers pay back to Medicaid. Under federal law, manufacturers must pay rebates to participate in Medicaid, and states generally must cover a participating manufacturer’s drugs in return. But states can still steer patients toward certain products by making some insulins easier to access than others through preferred status, quantity limits, or prior authorization requirements.
Managed Care Plans vs. Fee-for-Service
Most Medicaid enrollees today are in managed care plans run by private insurance companies contracted with the state. The insulin you’re offered can look quite different depending on whether your state runs a traditional fee-for-service program or routes you through a managed care organization.
The financial incentives behind the scenes explain why. Managed care organizations don’t keep the federal rebates that brand-name insulin manufacturers pay. States collect those rebates instead. So managed care plans are financially motivated to put lower-cost biosimilar and generic insulins on their formularies, since the list price is what matters to their bottom line. Fee-for-service Medicaid, on the other hand, benefits directly from those manufacturer rebates, which can make expensive brand-name insulins cheaper after rebates than their biosimilar alternatives.
The numbers bear this out. Nationally, biosimilar insulin glargine (the long-acting insulin most commonly prescribed for type 1 and type 2 diabetes) captured about 60.5% of the market in Medicaid managed care plans, compared to just 3.7% in fee-for-service Medicaid. In states where managed care plans weren’t required to follow a statewide preferred drug list, biosimilar insulin glargine use reached 59.1%. In states with only fee-for-service Medicaid, it was under 1%.
What this means for you: if you’re in a Medicaid managed care plan, your formulary is more likely to favor a biosimilar insulin over the brand-name version. If your doctor writes a prescription for a specific brand, you may need prior authorization or may be switched to the biosimilar equivalent. Both contain the same active ingredient and work the same way.
What You’ll Pay Out of Pocket
Medicaid copays for prescriptions are far lower than what you’d pay with private insurance or no insurance at all. Federal law caps total out-of-pocket costs for Medicaid enrollees at 5% of family income, and individual copays for prescription drugs are limited to nominal amounts. For most Medicaid beneficiaries, this means paying a few dollars per insulin prescription, and some enrollees (including children and pregnant individuals) pay nothing.
It’s worth noting that the $35 monthly insulin cap you may have heard about applies specifically to Medicare, not Medicaid. That provision, created by the Inflation Reduction Act, limits insulin copays for people enrolled in Medicare prescription drug plans. Medicaid already had its own cost protections in place, and most Medicaid enrollees were paying less than $35 per month for insulin before the cap existed.
Biosimilar Insulins Are Gaining Ground
The insulin landscape in Medicaid has shifted meaningfully toward biosimilar products. Biosimilar insulins are near-identical copies of brand-name insulins that have been reviewed and approved by the FDA. Some have earned “interchangeable” status, meaning a pharmacist can substitute them for the brand-name product without needing your doctor’s permission, similar to how generic medications work.
Data from prescription dispensing patterns show that newer interchangeable biosimilar insulin glargine products have been adopted quickly in Medicaid. In the first 14 months after one interchangeable product launched, its Medicaid dispensing grew steadily, outpacing earlier biosimilar versions that lacked the interchangeable designation. This trend suggests that Medicaid plans are increasingly favoring these products, which tend to carry lower list prices. For you as a patient, this may mean your pharmacy fills your long-acting insulin prescription with a biosimilar rather than the original brand.
Coverage for Insulin Pumps and Monitors
Insulin itself is covered, but the technology that helps deliver and manage it has more uneven coverage across state Medicaid programs. Insulin pumps and continuous glucose monitors (devices worn on the body that track blood sugar around the clock) are covered by Medicaid in many states, but often with medical necessity requirements that create extra barriers.
California offers a useful example of how these requirements have evolved. Until 2022, Medicaid-enrolled individuals in California who needed a continuous glucose monitor had to demonstrate they were testing their blood sugar at least three times per day and show specific concerns about dangerous blood sugar drops. Starting January 2022, California removed those extra requirements, making access significantly easier. Automated insulin delivery systems, which combine a pump with a glucose monitor to adjust insulin doses automatically, still carry additional requirements in many states, including lab tests and a minimum diabetes diagnosis period of six months.
If You’re Enrolled in Both Medicare and Medicaid
About 12 million Americans are “dual eligibles,” meaning they qualify for both Medicare and Medicaid. If you’re one of them, your insulin is primarily covered through Medicare’s prescription drug benefit (Part D), not Medicaid’s pharmacy benefit. Medicare handles inpatient, outpatient, and pharmacy spending, while Medicaid fills in gaps by covering things like long-term care and certain services Medicare doesn’t include.
For dual eligibles, the $35 monthly insulin cap from the Inflation Reduction Act does apply, since your insulin runs through Medicare Part D. Medicaid may still help cover any remaining cost-sharing, depending on your state’s rules for dual-eligible enrollees.
Emergency Insulin Access While Waiting for Medicaid
One gap that catches people off guard is the period between applying for Medicaid and actually having active coverage. If you need insulin urgently during that window, some states have created safety-net programs. Illinois, for instance, established an urgent-need insulin program that allows individuals to get a supply from a pharmacy with a valid prescription and proof of state residency. Notably, this program is designed for people who are not yet enrolled in Medicaid. If you’ve applied but haven’t been approved yet, or have been approved but your coverage hasn’t kicked in, you can access an initial urgent-need supply and an additional 30-day refill under the program.
Not every state has a program like this, but the number of states with emergency insulin access laws has grown in recent years. If you’re in a gap period, ask your pharmacist or contact your state’s Medicaid office about options available to you.